CN101267808A - 新型制剂 - Google Patents

新型制剂 Download PDF

Info

Publication number
CN101267808A
CN101267808A CNA2006800344737A CN200680034473A CN101267808A CN 101267808 A CN101267808 A CN 101267808A CN A2006800344737 A CNA2006800344737 A CN A2006800344737A CN 200680034473 A CN200680034473 A CN 200680034473A CN 101267808 A CN101267808 A CN 101267808A
Authority
CN
China
Prior art keywords
tablet composition
pharmaceutical tablet
alkyl group
low alkyl
pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800344737A
Other languages
English (en)
Chinese (zh)
Inventor
H·A·阿迈德
S·佩奇
N·H·莎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37671050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101267808(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN101267808A publication Critical patent/CN101267808A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2006800344737A 2005-09-23 2006-09-13 新型制剂 Pending CN101267808A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71979305P 2005-09-23 2005-09-23
US60/719,793 2005-09-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410122989.3A Division CN103893145A (zh) 2005-09-23 2006-09-13 新型制剂

Publications (1)

Publication Number Publication Date
CN101267808A true CN101267808A (zh) 2008-09-17

Family

ID=37671050

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2006800344737A Pending CN101267808A (zh) 2005-09-23 2006-09-13 新型制剂
CN201410122989.3A Pending CN103893145A (zh) 2005-09-23 2006-09-13 新型制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410122989.3A Pending CN103893145A (zh) 2005-09-23 2006-09-13 新型制剂

Country Status (26)

Country Link
US (3) US20070071813A1 (da)
EP (1) EP1928427B1 (da)
JP (2) JP5523706B2 (da)
KR (1) KR20080043852A (da)
CN (2) CN101267808A (da)
AR (1) AR056198A1 (da)
AT (1) ATE453384T1 (da)
AU (1) AU2006298898B2 (da)
BR (1) BRPI0616108A2 (da)
CA (1) CA2623237C (da)
DE (1) DE602006011485D1 (da)
DK (1) DK1928427T3 (da)
ES (1) ES2335922T3 (da)
HK (1) HK1198914A1 (da)
HR (1) HRP20100111T1 (da)
IL (1) IL189929A (da)
MY (1) MY143784A (da)
NO (1) NO340473B1 (da)
NZ (1) NZ566419A (da)
PL (1) PL1928427T3 (da)
PT (1) PT1928427E (da)
RU (1) RU2431473C2 (da)
SI (1) SI1928427T1 (da)
TW (1) TWI375572B (da)
WO (1) WO2007039420A1 (da)
ZA (1) ZA200802272B (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108159008A (zh) * 2018-02-27 2018-06-15 河北化工医药职业技术学院 缬沙坦咀嚼片的制备方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3208272B1 (en) 2005-11-08 2020-01-08 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2164840A2 (en) 2007-05-09 2010-03-24 Vertex Pharmaceuticals Incorporated Modulators of cftr
DE102007027067A1 (de) * 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
RS55559B1 (sr) 2007-12-07 2017-05-31 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline
EA201070700A1 (ru) 2007-12-07 2011-06-30 Вертекс Фармасьютикалз Инкорпорейтед Способы получения циклоалкилкарбоксамидопиридинбензойных кислот
WO2009087410A2 (en) * 2008-01-11 2009-07-16 Cipla Limited Solid pharmaceutical dosage form
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
NZ602838A (en) 2010-04-07 2015-06-26 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
JP5917964B2 (ja) * 2012-03-19 2016-05-18 富士ゼロックス株式会社 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム
CN105745198B (zh) 2013-11-08 2018-09-21 橘生药品工业株式会社 羧甲基哌啶衍生物
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
CN107107463B (zh) * 2014-09-08 2019-10-25 中央兰开夏大学 固体剂型生产
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
CN104586770A (zh) * 2014-12-30 2015-05-06 山东博迈康药物研究有限公司 一种盐酸帕唑帕尼的热熔挤出制剂及其制备方法
CN111344287B (zh) 2017-11-14 2023-12-19 默沙东有限责任公司 作为吲哚胺2，3-双加氧酶(ido)抑制剂的新型取代的联芳基化合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
EP0089765A3 (en) 1982-03-17 1984-05-23 Smith Kline & French Laboratories Limited Pyridine derivatives
JPS60184008A (ja) * 1984-03-02 1985-09-19 Eisai Co Ltd テオフイリンまたはアミノフイリン含有組成物
US4745123A (en) 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1994003429A1 (en) * 1992-07-31 1994-02-17 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
AU6807994A (en) 1993-05-28 1994-12-20 Taisho Pharmaceutical Co., Ltd. Medicinal use of pyridine derivative
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
SG52217A1 (en) 1993-12-29 1998-09-28 Merck Sharp & Dohme Substituted morpholine derivatives and their use as therapeutic agents
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
PT764163E (pt) 1994-06-06 2002-03-28 Warner Lambert Co Antagonistas do receptor de taquiquinina (nk1)
JP3884476B2 (ja) 1994-06-24 2007-02-21 大正製薬株式会社 ピリジン誘導体
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6294537B1 (en) * 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
ES2194937T3 (es) 1995-03-24 2003-12-01 Takeda Chemical Industries Ltd Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina.
ATE261942T1 (de) 1996-03-29 2004-04-15 Pfizer 6-phenylpyridinderivate
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
WO1998021185A1 (fr) 1996-11-08 1998-05-22 Sankyo Company, Limited Arylurees ou derives d'arylmethylcarbamyle
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
JPH11189548A (ja) * 1997-12-25 1999-07-13 Toshio Sato 無晶性医薬組成物及びその製造方法
JPH11189546A (ja) 1997-12-25 1999-07-13 Saitama Daiichi Seiyaku Kk 経皮吸収促進剤
RU2238264C2 (ru) 1999-02-24 2004-10-20 Ф.Хоффманн-Ля Рош Аг Производные бензола или пиридина и фармацевтическая композиция на их основе
PT1394150E (pt) * 1999-02-24 2011-02-17 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilização como antagonistas dos receptores de nc-1
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
EP1103545B1 (en) * 1999-11-29 2003-11-05 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
NZ528689A (en) * 2001-05-03 2005-03-24 F Pharmaceutical dosage form of amorphous nelfinavir mesylate
KR100810320B1 (ko) 2005-06-16 2008-03-04 삼성전자주식회사 디지털 방송 재생기가 방송 중에 제공되는 전화번호를이용하여 발신하는 방법 및 그 디지털 방송 시스템

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108159008A (zh) * 2018-02-27 2018-06-15 河北化工医药职业技术学院 缬沙坦咀嚼片的制备方法

Also Published As

Publication number Publication date
CA2623237C (en) 2013-07-09
EP1928427B1 (en) 2009-12-30
MY143784A (en) 2011-07-15
RU2008109823A (ru) 2009-10-27
BRPI0616108A2 (pt) 2011-06-07
RU2431473C2 (ru) 2011-10-20
HRP20100111T1 (hr) 2010-04-30
NZ566419A (en) 2010-03-26
PT1928427E (pt) 2010-03-01
EP1928427A1 (en) 2008-06-11
DE602006011485D1 (de) 2010-02-11
AU2006298898A1 (en) 2007-04-12
US8852634B2 (en) 2014-10-07
US20110070303A1 (en) 2011-03-24
JP2013049686A (ja) 2013-03-14
HK1198914A1 (en) 2015-06-19
AU2006298898B2 (en) 2011-06-30
AR056198A1 (es) 2007-09-26
CN103893145A (zh) 2014-07-02
ZA200802272B (en) 2009-01-28
NO340473B1 (no) 2017-04-24
CA2623237A1 (en) 2007-04-12
IL189929A0 (en) 2008-08-07
TW200803922A (en) 2008-01-16
PL1928427T3 (pl) 2010-06-30
US20130189362A1 (en) 2013-07-25
IL189929A (en) 2012-12-31
DK1928427T3 (da) 2010-03-08
JP2009508907A (ja) 2009-03-05
ATE453384T1 (de) 2010-01-15
NO20081325L (no) 2008-06-18
TWI375572B (en) 2012-11-01
KR20080043852A (ko) 2008-05-19
ES2335922T3 (es) 2010-04-06
WO2007039420A1 (en) 2007-04-12
JP5523706B2 (ja) 2014-06-18
US20070071813A1 (en) 2007-03-29
SI1928427T1 (sl) 2010-03-31

Similar Documents

Publication Publication Date Title
CN101267808A (zh) 新型制剂
JP2010509289A (ja) チロシンキナーゼ阻害剤の経口投与用薬学的剤形
AU2016263338B2 (en) SOMCL-9112 solid dispersion and preparation method thereof and SOMCL-9112 solid preparation containing SOMCL-9112 solid dispersion
JP6537147B2 (ja) 固体分散体
WO2009100176A2 (en) Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
AU2011205164A1 (en) Compositions, suitable for oral administration, comprising a triazolo (4, 5-d) pyrimidin derivate
CN101304731A (zh) 醋酸苯卓昔芬制剂及其生产方法
RU2639818C2 (ru) Фармацевтическое комбинированное лекарственное средство
CN113925833A (zh) 包含酪氨酸蛋白激酶抑制剂的剂型组合物
TW200848056A (en) Solid dispersion of a neurokinin antagonist
EP2291079B1 (en) Formulations for cathepsin k inhibitors
CN104706640B (zh) 一种含有厄贝沙坦的药用组合物及其制备工艺
AU2010206224A1 (en) Pharmaceutical compositions comprising a HCV polymerase inhibitor prodrug
NZ760233A (en) Compositions and methods for treatment of abnormal cell growth
EP2425859A1 (en) Olmesartan formulations
EP3620156A1 (en) Composition having improved water solubility and bioavailability
CN102198107B (zh) 拉西地平分散片及其制备方法
WO2021164755A1 (zh) 奥拉帕尼药物组合物及其制剂、制备方法和用途
CN113134007A (zh) 一种醋酸阿比特龙口服制剂及其制备方法
CN117482055A (zh) 一种低剂量盐酸决奈达隆片的制备方法
CN117771248A (zh) 一种依折麦布瑞舒伐他汀钙制剂及其制备方法
WO2012062691A1 (en) Pharmaceutical compositions for treating hcv infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1124249

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080917

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1124249

Country of ref document: HK